35 articles
A Saudi Arabia survey reveals alarming gaps in ApoB testing knowledge among physicians and pharmacists, despite clear guideline recommendations.
A simulation of 250,000 adults finds using apoB goals to guide lipid-lowering therapy costs just $30,300 per QALY gained vs. non-HDL-C, making it highly cost-effective.
Elevated oxidized phospholipids independently predict major cardiac events after ACS, and alirocumab abolishes that risk signal.
A systematic review of 593,354 participants finds apoB consistently outperforms LDL-C and non-HDL-C for predicting cardiovascular disease risk.
Simon Hill's cardiovascular masterclass covers the Portfolio Diet, plaque regression, ApoB testing, and the sodium-potassium ratio with top experts.
Phase 4 trial tests whether alirocumab can better control non-HDL cholesterol in high-risk type 2 diabetics failing statin therapy.
A genomic study of 3,358 biopsy-proven MASLD patients finds APOB pathogenic variants linked to significantly higher steatosis and liver injury scores.
A mass spectrometry apolipoprotein panel predicts cardiovascular events and identifies who gains the most from PCSK9 inhibitor therapy.
A 94,000-person study finds high remnant cholesterol raises heart disease risk 45% — yet triggers far less statin prescribing than high LDL.
A new study finds elevated apolipoprotein B strongly predicts reduced myocardial flow reserve, deepening its role in cardiovascular risk.
A formula using standard lipid panels estimates small, dense LDL and outperforms LDL-C and rivals ApoB in predicting ASCVD risk across 271,760 adults.
A 2026 practical review exposes critical gaps in lipid management and outlines updated strategies to slash cardiovascular risk.
